Fosun Pharma’s Zhangjiang Innovation and R&D Park which was built from 2012. is located in R&D of high-technology in Pharmaceutical industry and the integration platform of Fosun Pharma R&D Innovation and pilot scale system will be built in the future.
Fosun Pharma innovatively integrates domestic resources and constantly enhances its R&D capacity. Fosun Pharma, together with domestic famous scientific research institutes and enterprises establishes“Strategic Alliance of Fosun Pharma”, one of the “Industry-university-research Alliance” in National Science and Technology Major Project of the Ministry of Science and Technology of China. In June, 2014, “Strategic Alliance of Fosun Pharma”,which is one of the “Industry-university-research Alliance” in National Science and Technology Major Project of the Ministry of Science and Technology of China successfully passed the acceptanceand and was highly praised by the relevant departments of the state. Fosun Pharma carries out a comprehensively strategic cooperation with Shanghai Institute of Materia Medica of China Academy of Sciences, building a new development community. Establish a Industry-university-research Alliance with Shanghai University of Traditional Chinese Medicine and set up “Fosun Pharmaceutical Innovation Fund on Chinese Medicine Technology” to formulate an innovative Chinese medicine R&D platform under the cooperation between schools and enterprises. Accelerate the transformation of scientific and technological achievements in traditional Chinese medicine in Shanghai University of Traditional Chinese Medicine to promote the industrialization development of traditional Chinese medicine. Cooperate with Dalian Wanchun to set up a joint venture and develop innovative anti-tumor medicines with international patent licensing.
As for international technical resources, Fosun Pharma jointly sets up Lonza Fosun Company with Lonza Group, a leading Swiss supplier in the world’s pharmaceuticals, healthcare and life sciences areas. The company focuses on tumor, infection and cardiovascular therapy, jointly develop generic drugs of high technical barriers which the Chinese market needs badly. Meanwhile, cooperate with Handa in America, Amerigen in Suzhou to develop high-value generic drugs registered both in China and abroad.